Exheus

Exheus operates in the burgeoning field of personalized health, leveraging a proprietary combination of RNA sequencing and artificial intelligence to provide deep insights into an individual's health. Founded in June 2020, the company emerged as a spin-off from the Sant Pau Hospital Research Institute (IIB Sant Pau), the Polytechnic University of Catalonia (UPC), and was fostered by the Mobile World Capital Barcelona's 'The Collider' innovation program. The scientific foundation of Exheus stems from the doctoral thesis of co-founder Dr. Emma Roca, a biochemist and elite ultrarunner who sought to analyze the effects of high-intensity sport. She was joined by CEO Dr. Teresa Tarragó, who holds a PhD in Molecular Biology and an MBA, and Pol Cervera, who serves as the director of operations, to provide the business acumen needed to bring the technology to market.

The core of Exheus's offering is a health test that analyzes a small blood sample to sequence messenger RNA (mRNA). This process provides a real-time snapshot of the activation levels of all 22,000 human genes. The vast amount of data is then processed by the company's AI algorithms to identify alterations across more than 320 metabolic pathways. This analysis translates into a detailed, personalized report with actionable recommendations concerning nutrition and lifestyle adjustments to improve well-being and prevent health issues. The company's technology is designed to move beyond probabilistic genetic tests by showing exactly how the body is reacting to diet, exercise, and other environmental factors at a given moment.

Exheus serves two primary client segments. For individuals and health-conscious consumers, it offers products like 'Exheus Nutri Diet' for general wellness and nutrition guidance. The company also targets the B2B market, particularly high-performance sports, with its 'Exheus Blue Boost' test, which helps optimize athletic performance and reduce injury recovery times. Pilot programs have been conducted with top European sports clubs. To further serve the professional market, Exheus launched 'Beyond You' in July 2023, a digital platform enabling healthcare professionals to directly access and utilize the test results to optimize patient diagnosis and treatment. The business model is based on the sale of these advanced genetic tests and reports. To date, Exheus has secured $935K in funding over four rounds, including from investors like Decelera Ventures, Ship2B, and grants from EIT Health and the European Union, which will support European expansion and the development of its B2B platform.

Keywords: RNA sequencing, gene expression analysis, artificial intelligence in health, personalized nutrition, sports performance optimization, preventative medicine, biomarker discovery, metabolic pathway analysis, health-tech, bioinformatics, genetic testing, wellness report, sports science, B2B health platform, nutrigenomics, personalized medicine, molecular diagnostics, blood analysis, AI-driven health insights, biotech